Phase 4 Rheumatoid Arthritis Trial, Recruiting NCT05626348 Sponsor: Qilu Hospital of Shandong University Condition: Rheumatoid Arthritis
Back to Rheumatoid Arthritis

Phase 4 Rheumatoid Arthritis Trial, Recruiting

NCT05626348
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with Rheumatoid Arthritis (RA) using recognised medical guidelines, AND you have problems with your knee function.
  • You meet the 1987 RA classification by having at least 4 of these 7 signs: morning stiffness lasting at least 1 hour (for 6+ weeks); 3 or more swollen joint areas (for 6+ weeks); swelling in the wrist or finger joints (for 6+ weeks); matching swelling on both sides of the body (for 6+ weeks); specific hand X-ray changes; or a positive rheumatoid factor blood test (confirm with trial site).
  • Alternatively, you may qualify under 2010 RA guidelines, which use a scoring system based on which joints are affected, certain blood test results, inflammation markers, and how long symptoms have lasted (confirm with trial site).
  • OR you have been diagnosed with Osteoarthritis (OA) of the knee, with most-days knee pain in the last month, plus other specific signs such as a grating sound in the knee, morning stiffness lasting 30 minutes or less, being aged 38 or older, or bony enlargement around the knee.
  • OR you are a healthy volunteer of a similar age and sex to the patients, who has had a check-up at the hospital involved in the trial.
  • You are over 18 years old.
  • You are willing to take part and are able to sign a consent form.

Who may not be able to join:

  • People who currently have active hepatitis (a liver infection).
  • People who currently have active tuberculosis (TB).
  • People who currently have an active infection of any kind, or who have been diagnosed with cancer.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Xiaoyun Yang, Qilu Hospital of Shandong University

Phone: 0086-0531-82169654

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Sponsor
Qilu Hospital of Shandong University
Registry
ClinicalTrials.gov
Start date
22 December 2021
Est. completion
30 June 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

The percentage of patients who achieve clinical remission using European League Against Rheumatism (EULAR) response criteria DAS28.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov